Literature DB >> 10524283

Impact of age and amyloidosis on thiol conjugation of transthyretin in hereditary transthyretin amyloidosis.

O B Suhr1, I H Svendsen, P I Ohlsson, J Lendoire, P Trigo, K Tashima, P J Ranløv, Y Ando.   

Abstract

Variant forms and post-translational modifications of transthyretin (TTR) can be identified by electrospray ionisation mass spectrometry (ESI-MS). The aim of the present study was to investigate thiol conjugation of transthyretin and it's relation to age and symptomatic amyloid disease in different populations of variant TTR carriers. Plasma samples from 70 individuals from Denmark, Argentina, Sweden and Japan, with 2 different TTR mutations were analysed. The percentage cysteine (Cys) conjugated wild and variant TTR were calculated from the corresponding peaks of the spectra, and multiple regression analysis was employed to disclose relationships between age, symptomatic amyloid disease and origin. Age, origin and presence of symptomatic disease, were found to be independent factors related to transthyretin conjugation. A higher percentage of conjugated to unconjugated TTR was disclosed in symptomatic, but not in asymptomatic carriers. In summary: Thiol conjugation of TTR is dependent on age and presence of symptomatic amyloid disease. Furthermore, it varies between different populations. Variant TTR is more susceptible to thiol conjugation than the wild type. Post-translational factors may be related to amyloid formation and/or toxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10524283     DOI: 10.3109/13506129909007325

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  5 in total

1.  Plasma biomarkers of mouse aging.

Authors:  Juan Ding; John J Kopchick
Journal:  Age (Dordr)       Date:  2010-09-15

2.  Expression, purification, and in vitro cysteine-10 modification of native sequence recombinant human transthyretin.

Authors:  Jonathan S Kingsbury; Elena S Klimtchuk; Roger Théberge; Catherine E Costello; Lawreen H Connors
Journal:  Protein Expr Purif       Date:  2007-01-17       Impact factor: 1.650

3.  Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis.

Authors:  Amareth Lim; Tatiana Prokaeva; Mark E McComb; Lawreen H Connors; Martha Skinner; Catherine E Costello
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

4.  The modulation of transthyretin tetramer stability by cysteine 10 adducts and the drug diflunisal. Direct analysis by fluorescence-detected analytical ultracentrifugation.

Authors:  Jonathan S Kingsbury; Thomas M Laue; Elena S Klimtchuk; Roger Théberge; Catherine E Costello; Lawreen H Connors
Journal:  J Biol Chem       Date:  2008-03-06       Impact factor: 5.157

5.  Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis.

Authors:  Hiroaki Matsushita; Yohei Misumi; Teruaki Masuda; Masamitsu Okada; Fumika Inoue; Mitsuharu Ueda; Yukio Ando
Journal:  Pathophysiology       Date:  2022-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.